HEAR评分在急诊胸痛患者中免肌钙蛋白排除主要不良心脏事件的安全性评估
前瞻性观察研究在6个急诊科纳入非创伤性胸痛且无替代诊断的患者,随访45天。主要终点为HEAR评分<2患者的45天MACE率,安全性标准为<1%且95%CI上限<3%。1402例分析中97例(7%)发生MACE;HEAR<2者279例(20%)中仅1例MACE[0.4%(95%CI 0.01-1.98)]。两步HEART策略额外将476例(34%)归为低危,其中1例MACE[0.3%(95%CI 0.03-0.95)],理论上避免360次肌钙蛋白检测(19%)。
要点
- HEAR评分<2在急诊非创伤性胸痛患者中排除45天MACE安全:279例中1例MACE[0.4%(95%CI 0.01-1.98)],95%CI上限<3%。
- 两步HEART策略(先HEAR<2,再HEART<4)额外识别476例(34%)低危患者,其中1例MACE[0.3%(95%CI 0.03-0.95)]。
- 两步策略理论上可避免360次肌钙蛋白检测,占全部检测的19%。
- 研究为前瞻性多中心观察性研究,纳入6个急诊科1452例,1402例完成分析,总体MACE率7%。
适用人群与场景
- 6个急诊科就诊的非创伤性胸痛且无替代诊断的患者,随访45天。
诊断标准与关键阈值
- HEAR评分<2定义为低危;两步HEART策略中HEART评分<4定义为低危。
- HEAR评分<2策略安全性标准:45天MACE率<1%且95%CI上限<3%。
处置流程与药物剂量
- 第一步:计算HEAR评分(不含肌钙蛋白),若<2可考虑免肌钙蛋白排除MACE。
- 第二步:若HEAR评分未达低危,进一步计算HEART评分(含肌钙蛋白),若<4归为低危。
红旗征与不能漏的情况
- 原文未提及具体红旗征或需立刻处理的情况。
研究设计与关键结果
- 前瞻性观察性研究,6个急诊科,纳入1452例,分析1402例,45天随访。
- 总体97例(7%)发生MACE。
- HEAR<2者279例(20%),1例MACE[0.4%(95%CI 0.01-1.98)]。
- 两步HEART策略额外低危476例(34%),其中1例MACE[0.3%(95%CI 0.03-0.95)]。
- 两步策略理论上避免360次肌钙蛋白检测(19%)。
证据类型、等级与局限
- 证据类型:前瞻性多中心观察性研究。
- 局限:观察性设计,原文未提及盲法或样本量计算;安全性结论基于95%CI上限<3%的预设标准。
对床旁实践的改变
- 对急诊非创伤性胸痛且无替代诊断的患者,HEAR评分<2可支持免肌钙蛋白排除MACE,减少不必要的血液检测。
- 两步HEART策略可在HEAR评分基础上进一步减少19%的肌钙蛋白检测,但需注意该策略为序贯评估,不适用于已明确非STEMI需肌钙蛋白检测的患者。
- 常见陷阱:HEAR评分<2的低危患者仍有0.4%的MACE风险,需结合临床判断并确保随访。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND IMPORTANCE: Current guidelines for patients presenting to the emergency department with chest pain without ST-segment elevation myocardial infarction (non-STEMI) on electrocardiogram are based on troponin measurement. The HEART score is reportedly a reliable work-up strategy that combines clinical evaluation with troponin value. A clinical rule that could select very low-risk patients without the need for a blood test (HEAR score, being the HEART score without the troponin item) would be of great interest.
OBJECTIVES: To prospectively assess the safety of a HEAR score <2 to rule-out non-STEMI without troponin measurement. Secondary objective was to assess the safety of a sequential strategy that combines HEAR score and HEART (defined as two-step HEART strategy).
DESIGN, SETTINGS AND PARTICIPANTS: Prospective observational study in six emergency departments. Patients with nontraumatic chest pain and no alternative diagnosis were included and followed up for 45 day. Patients were considered at low-risk if the HEAR score was <2 or, for the two-step HEART strategy, if the HEART score was <4.
OUTCOMES MEASURE AND ANALYSIS: The primary endpoint was the 45-day rate of major adverse cardiac events (MACE) in patients with a HEAR score <2. A HEAR score based strategy was consider safe if the rate of the primary endpoint was below 1%, with an upper margin of the 95% confidence interval (CI) below 3%.
RESULTS: Among 1452 patients included, 1402 were analyzed and 97 (7%) had a MACE during the follow-up period. The HEAR score was <2 in 279 (20%) patients and one presented a MACE [0.4% (95% CI: 0.01-1.98)]. The two-step HEART strategy classified low-risk an additional 476 patients (34%) and one of these 476 patients had a MACE [0.3% (95% CI: 0.03-0.95)]. The two-step HEART strategy would have theoretically avoided 360 troponin measurements (19%).
CONCLUSIONS: In our prospective multicenter study, a HEAR based work-up strategy was safe, with a very low risk of MACE at 45 day. We also report that a two-step HEART-based strategy may safely allow significant reduction of troponin measurements in patients presenting to the emergency department with chest pain.
参考来源
- Moumneh T, Penaloza A, Cismas A, et al. Evaluation of HEAR score to rule-out major adverse cardiac events without troponin test in patients presenting to the emergency department with chest pain. Eur J Emerg Med. 2021. PMID: 34187993. doi:10.1097/MEJ.0000000000000791
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。